{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:34:49Z","timestamp":1774967689863,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To describe, compare similarity of pharmacokinetic (PK), pharmacodynamic (PD) and efficacy of SB12 and reference eculizumab (ECU) and find clinically significant covariate relationships.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The PK, PD (terminal complement activity) and efficacy (LDH) data of SB12 and ECU were obtained from 289 subjects from phase I and phase III studies. One- and two-compartment PK models with first-order elimination were evaluated for SB12 and ECU. For PD and efficacy, both direct and indirect models were tested. The impact of covariates on PK, PD and efficacy parameters was assessed. Relationship between PK\/PD and PD\/efficacy was characterized. This modeling was performed using NONMEM version 7.4 (Icon Development Solutions, Ellicott City, MD, USA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The two-compartment model adequately described the PK of SB12 and ECU, and the subject\u2019s weight was chosen as a clinically significant covariate affecting drugs\u2019 clearance and central volume of distribution. Treatment group was not a significant covariate affecting clearance. The direct response model using inhibitory sigmoid <jats:italic>E<\/jats:italic><jats:sub>max<\/jats:sub> and sigmoid <jats:italic>E<\/jats:italic><jats:sub>max<\/jats:sub> relationship well described the PK\/PD relationship and PD\/efficacy relationship of SB12 and ECU, respectively. Through this modeling, the relationships between PK, PD and efficacy were characterized. There were no differences in PK, PD and efficacy parameters between SB12 and ECU in pooled populations of healthy subjects and paroxysmal nocturnal haemoglobinuria (PNH) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The population modeling showed PK, PD and efficacy similarities between SB12 and ECU in pooled population of healthy subjects and PNH patients, supporting the totality of evidence on biosimilarity for SB12.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-024-03703-8","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T07:07:29Z","timestamp":1717052849000},"page":"1325-1338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab"],"prefix":"10.1007","volume":"80","author":[{"given":"Hyuna","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihye","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyerin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungryul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"3703_CR1","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, Dezern AE, Kinoshita T, Brodsky RA (2017) Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers 3:17028","journal-title":"Nat Rev Dis Primers"},{"key":"3703_CR2","unstructured":"Shah N, Bhatt H (2023) Paroxysmal nocturnal hemoglobinuria [Book] StatPearls Publishing"},{"issue":"18","key":"3703_CR3","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA (2014) Paroxysmal nocturnal haemoglobinuria. Blood 124(18):2804\u20132811","journal-title":"Blood"},{"issue":"4","key":"3703_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","volume":"73","author":"J Takeda","year":"1993","unstructured":"Takeda J, Miyata T, Kawagoe K et al (1993) Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73(4):703\u2013711","journal-title":"Cell"},{"issue":"5","key":"3703_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/jcm9051261","volume":"9","author":"G Gembillo","year":"2020","unstructured":"Gembillo G, Siligato R, Cernaro V, Santoro D (2020) Complement inhibition therapy and dialytic strategies in paroxysmal nocturnal hemoglobinuria: The Nephrologist\u2019s Opinion. J Clin Med 9(5):1261. https:\/\/doi.org\/10.3390\/jcm9051261","journal-title":"J Clin Med"},{"issue":"6","key":"3703_CR6","first-page":"605","volume":"61","author":"S Tamura","year":"2020","unstructured":"Tamura S, Furuya Y, Hori Y et al (2020) Paroxysmal nocturnal hemoglobinuria treated with eculizumab in Wakayama, Japan: a retrospective analysis. Rinsho Ketsueki 61(6):605\u2013611","journal-title":"Rinsho Ketsueki"},{"issue":"10","key":"3703_CR7","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.bbmt.2020.05.024","volume":"26","author":"M Markiewicz","year":"2020","unstructured":"Markiewicz M, Drozd-Sokolowska J, Biecek P et al (2020) Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: multicenter analysis by the polish adult leukemia group. Biol Blood Marrow Transplant 26(10):1833\u20131839","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"3703_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s40273-020-00929-z","volume":"38","author":"T O'Connell","year":"2020","unstructured":"O\u2019Connell T, Buessing M, Johnson S et al (2020) Cost-Utility Analysis of ravulizumab compared with eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria. Pharmacoeconomics 38(9):981\u2013999","journal-title":"Pharmacoeconomics"},{"key":"3703_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/14728214.2022.2031973","volume":"27","author":"C Frieri","year":"2022","unstructured":"Frieri C, Peffault de Latour R, Sicre De Fontbrune F (2022) Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Emerg Drugs 27:33\u201343","journal-title":"Expert Opin Emerg Drugs"},{"issue":"7","key":"3703_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Ter Heine R, Moes DJAR et al (2019) Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet 58(7):859\u2013874","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3703_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.tmrv.2019.09.004","volume":"33","author":"CJ Patriguin","year":"2019","unstructured":"Patriguin CJ, Kuo KHM (2019) Eculizumab and beyond: the past, present and future of complement therapeutics. Transfus Med Rev 33(4):256\u2013265","journal-title":"Transfus Med Rev"},{"issue":"3","key":"3703_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/j.seminhematol.2018.05.014","volume":"55","author":"R Notaro","year":"2018","unstructured":"Notaro R, Sica M (2018) C3-mediated extravascular hemolysis in PNH on eculizumab: mechanism and clinical implications. Semin Hematol 55(3):130\u2013135","journal-title":"Semin Hematol"},{"key":"3703_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/imj.13160","volume":"46","author":"G Soci\u00e9","year":"2016","unstructured":"Soci\u00e9 G, Schrezenmeier H, Muus P et al (2016) Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry. Intern Med J 46:1044\u20131053","journal-title":"Intern Med J"},{"key":"3703_CR14","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","volume":"106","author":"A Hill","year":"2005","unstructured":"Hill A, Hillmen P, Richards SJ et al (2005) Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 106:2559\u20132565","journal-title":"Blood"},{"key":"3703_CR15","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233\u20131243","journal-title":"N Engl J Med"},{"key":"3703_CR16","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E et al (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840\u20131847","journal-title":"Blood"},{"key":"3703_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JC et al (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552\u2013559","journal-title":"N Engl J Med"},{"key":"3703_CR18","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","volume":"110","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Muus P, D\u00fchrsen U et al (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110:4123\u20134128","journal-title":"Blood"},{"key":"3703_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ajh.21757","volume":"85","author":"P Hillmen","year":"2010","unstructured":"Hillmen P, Elebute M, Kelly R et al (2010) Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 85:553\u2013559","journal-title":"Am J Hematol"},{"key":"3703_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1365-2141.2010.08096.x","volume":"149","author":"A Hill","year":"2010","unstructured":"Hill A, Rother RP, Wang X et al (2010) Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnea, and measure of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 149:414\u2013425","journal-title":"Br J Haematol"},{"key":"3703_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2141.2012.09166.x","volume":"158","author":"A Hill","year":"2012","unstructured":"Hill A, Sapsford RJ, Scally A et al (2012) Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. Br J Haematol 158:409\u2013414","journal-title":"Br J Haematol"},{"key":"3703_CR22","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM et al (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117:6786\u20136792","journal-title":"Blood"},{"issue":"4","key":"3703_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40259-023-00591-9","volume":"37","author":"H Kim","year":"2023","unstructured":"Kim H, Hong E, Lee J et al (2023) Characterization for the similarity assessment between proposed biosimilar SB12 and eculizumab reference product using a state-of-art analytical method. BioDrugs 37(4):569\u2013581","journal-title":"BioDrugs"},{"issue":"6","key":"3703_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5414\/CP204176","volume":"60","author":"HA Lee","year":"2022","unstructured":"Lee HA, Jang H, Jeong D, Kim Y, Fuhr R (2022) A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects. Int J Clin Pharmacol Ther 60(6):269\u2013279","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"3703_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jha2.632","volume":"4","author":"JH Jang","year":"2022","unstructured":"Jang JH, Gomez RD, Bumbea H et al (2022) A phase III, randomized, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria. EJHeam 4(1):26\u201336","journal-title":"EJHeam"},{"key":"3703_CR26","unstructured":"European Medicines Agency (EMA)\u00a0(2007) Soliris: EPAR \u2013 scientific discussion, London: EMA"},{"issue":"5","key":"3703_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","volume":"125","author":"RP De Latour","year":"2015","unstructured":"De Latour RP, Fremeaux-Bacchi V, Porcher R et al (2015) Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 125(5):775\u2013783","journal-title":"Blood"},{"issue":"2","key":"3703_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10928-012-9240-x","volume":"39","author":"BD Lacroix","year":"2012","unstructured":"Lacroix BD, Friberg LE, Karlsson MO (2012) Evaluation of IPPSE, and alternative method for sequential population PKPD analysis. J Pharmacokinet Pharmacodyn 39(2):177\u2013193","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"3703_CR29","first-page":"116","volume":"5","author":"MR Balwani","year":"2015","unstructured":"Balwani MR, Kute VB, Shah PR et al (2015) Manifestation of paroxysmal nocturnal hemoglobinuria as repeated acute kidney injury. J Nephropharmacol 5(2):116\u2013118","journal-title":"J Nephropharmacol"},{"issue":"1\u20132","key":"3703_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000351345","volume":"123","author":"S Hussain","year":"2013","unstructured":"Hussain S, Qureshi A, Kazi J (2013) Renal involvement in paroxysmal nocturnal hemoglobinuria. Nephron Clin Pract 123(1\u20132):28\u201335","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"3703_CR31","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.nefroe.2018.04.004","volume":"38","author":"A Oruc","year":"2018","unstructured":"Oruc A, Ayar Y, Vuruskan BA et al (2018) Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia (Engl Ed) 38(4):448\u2013450","journal-title":"Nefrologia (Engl Ed)"},{"key":"3703_CR32","doi-asserted-by":"publisher","first-page":"S868","DOI":"10.14309\/00000434-201610001-01812","volume":"111","author":"A Mone","year":"2016","unstructured":"Mone A, Chang S, Poppers D (2016) Worsening hepatic function in paroxysmal nocturnal hemoglobinuria (PNH) leading to hemolysis, gallstones, and progressive hepatic fibrosis: 1812. Am J Gastroenterol 111:S868\u2013S869","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3703_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/ejh.13411","volume":"105","author":"V Chow","year":"2020","unstructured":"Chow V, Pan J, Chien D, Mytych DT, Hanes V (2020) A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP959 and eculizumab (Soliris\u00ae) in healthy male subjects. Eur J Haematol 105(1):66\u201374","journal-title":"Eur J Haematol"},{"key":"3703_CR34","unstructured":"US Food and Drug Administration (FDA)\u00a0(2007) Clinical pharmacology and biopharmaceutics review. Silver Spring US FDA"},{"issue":"2","key":"3703_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.12793\/tcp.2017.25.2.74","volume":"25","author":"S Choe","year":"2017","unstructured":"Choe S, Lee D (2017) Parameter estimation for sigmoid Emax models in exposure-response relationship. Transl Clin Pharmacol 25(2):75\u201384","journal-title":"Transl Clin Pharmacol"},{"key":"3703_CR36","doi-asserted-by":"crossref","unstructured":"Tilly OL, Gatault P, Semlali S et al (2024) Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics. Br J Clin Pharmacol 1\u201310","DOI":"10.1111\/bcp.16019"},{"key":"3703_CR37","unstructured":"Ultomiris assessment report EMA\/CHMP\/220699\/2019 (2019)"},{"key":"3703_CR38","unstructured":"BLA Multi-Disciplinary Review and Evaluation BLA 761108 \u2013 Ultomiris (ravulizumab) (2018)"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03703-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03703-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03703-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:03:48Z","timestamp":1722927828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03703-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3703"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03703-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The final study protocol was approved by the responsible local Independent Ethics Committee (IEC) in Germany, India, Republic of Korea, Malaysia, Mexico, Romania, Taiwan, Thailand and Ukraine","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each subject participating in the study","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors are employees of either Samsung Bioepis Co., Ltd. or of an organization contracted by Samsung Bioepis Co., Ltd. for the present study. There are no other relationships or activities that could appear to influence the submitted work","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}